FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567880212> ?p ?o ?g. }

• W2567880212 endingPage "2814" @default.
• W2567880212 startingPage "2805" @default.
• W2567880212 abstract "There is experimental and clinical evidence that some exanthematous allergic drug hypersensitivity reactions are mediated by drug-specific T cells. We hypothesized that the capacity of certain drugs to directly stimulate the innate immune system may contribute to generate drug-specific T cells. Here we analyzed whether abacavir, an HIV-1 reverse transcriptase inhibitor often inducing severe delayed-type drug hypersensitivity, can trigger innate immune activation that may contribute to its allergic potential. We show that abacavir fails to generate direct innate immune activation in human monocytes but potently triggers IL-1β release upon pro-inflammatory priming with phorbol ester or Toll-like receptor stimulation. IL-1β processing and secretion were sensitive to Caspase-1 inhibition, NLRP3 knockdown, and K+ efflux inhibition and were not observed with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying abacavir as a specific inflammasome activator. It further correlated with dose-dependent mitochondrial reactive oxygen species production and cytotoxicity, indicating that inflammasome activation resulted from mitochondrial damage. However, both NLRP3 depletion and inhibition of K+ efflux mitigated abacavir-induced mitochondrial reactive oxygen species production and cytotoxicity, suggesting that these processes were secondary to NLRP3 activation. Instead, depletion of cardiolipin synthase 1 abolished abacavir-induced IL-1β secretion, suggesting that mitochondrial cardiolipin release may trigger abacavir-induced inflammasome activation. Our data identify abacavir as a novel inflammasome-stimulating drug allergen. They implicate a potential contribution of innate immune activation to medication-induced delayed-type hypersensitivity, which may stimulate new concepts for treatment and prevention of drug allergies. There is experimental and clinical evidence that some exanthematous allergic drug hypersensitivity reactions are mediated by drug-specific T cells. We hypothesized that the capacity of certain drugs to directly stimulate the innate immune system may contribute to generate drug-specific T cells. Here we analyzed whether abacavir, an HIV-1 reverse transcriptase inhibitor often inducing severe delayed-type drug hypersensitivity, can trigger innate immune activation that may contribute to its allergic potential. We show that abacavir fails to generate direct innate immune activation in human monocytes but potently triggers IL-1β release upon pro-inflammatory priming with phorbol ester or Toll-like receptor stimulation. IL-1β processing and secretion were sensitive to Caspase-1 inhibition, NLRP3 knockdown, and K+ efflux inhibition and were not observed with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying abacavir as a specific inflammasome activator. It further correlated with dose-dependent mitochondrial reactive oxygen species production and cytotoxicity, indicating that inflammasome activation resulted from mitochondrial damage. However, both NLRP3 depletion and inhibition of K+ efflux mitigated abacavir-induced mitochondrial reactive oxygen species production and cytotoxicity, suggesting that these processes were secondary to NLRP3 activation. Instead, depletion of cardiolipin synthase 1 abolished abacavir-induced IL-1β secretion, suggesting that mitochondrial cardiolipin release may trigger abacavir-induced inflammasome activation. Our data identify abacavir as a novel inflammasome-stimulating drug allergen. They implicate a potential contribution of innate immune activation to medication-induced delayed-type hypersensitivity, which may stimulate new concepts for treatment and prevention of drug allergies." @default.
• W2567880212 created "2017-01-13" @default.
• W2567880212 creator A5035350837 @default.
• W2567880212 creator A5035895188 @default.
• W2567880212 creator A5054913838 @default.
• W2567880212 creator A5068472134 @default.
• W2567880212 creator A5073006852 @default.
• W2567880212 creator A5075420379 @default.
• W2567880212 creator A5076078511 @default.
• W2567880212 date "2017-02-01" @default.
• W2567880212 modified "2023-10-17" @default.
• W2567880212 title "Potent NLRP3 Inflammasome Activation by the HIV Reverse Transcriptase Inhibitor Abacavir" @default.
• W2567880212 cites W1487413042 @default.
• W2567880212 cites W1529674879 @default.
• W2567880212 cites W1636793459 @default.
• W2567880212 cites W1861790843 @default.
• W2567880212 cites W1932984089 @default.
• W2567880212 cites W1971915082 @default.
• W2567880212 cites W1978274182 @default.
• W2567880212 cites W1979991507 @default.
• W2567880212 cites W1985538633 @default.
• W2567880212 cites W2003301452 @default.
• W2567880212 cites W2014533894 @default.
• W2567880212 cites W2018563185 @default.
• W2567880212 cites W2019855029 @default.
• W2567880212 cites W2026441558 @default.
• W2567880212 cites W2048226187 @default.
• W2567880212 cites W2051658957 @default.
• W2567880212 cites W2056295780 @default.
• W2567880212 cites W2058803210 @default.
• W2567880212 cites W2067406680 @default.
• W2567880212 cites W2068633454 @default.
• W2567880212 cites W2079882002 @default.
• W2567880212 cites W2082355065 @default.
• W2567880212 cites W2089378839 @default.
• W2567880212 cites W2092894443 @default.
• W2567880212 cites W2109491705 @default.
• W2567880212 cites W2113010696 @default.
• W2567880212 cites W2120815988 @default.
• W2567880212 cites W2126384811 @default.
• W2567880212 cites W2134373673 @default.
• W2567880212 cites W2135117972 @default.
• W2567880212 cites W2140055542 @default.
• W2567880212 cites W2140637559 @default.
• W2567880212 cites W2145736817 @default.
• W2567880212 cites W2147810846 @default.
• W2567880212 cites W2158965677 @default.
• W2567880212 cites W2162112031 @default.
• W2567880212 cites W2169444017 @default.
• W2567880212 cites W2334301577 @default.
• W2567880212 doi "https://doi.org/10.1074/jbc.m116.749473" @default.
• W2567880212 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5314176" @default.
• W2567880212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28057759" @default.
• W2567880212 hasPublicationYear "2017" @default.
• W2567880212 type Work @default.
• W2567880212 sameAs 2567880212 @default.
• W2567880212 citedByCount "35" @default.
• W2567880212 countsByYear W25678802122017 @default.
• W2567880212 countsByYear W25678802122018 @default.
• W2567880212 countsByYear W25678802122019 @default.
• W2567880212 countsByYear W25678802122020 @default.
• W2567880212 countsByYear W25678802122021 @default.
• W2567880212 countsByYear W25678802122022 @default.
• W2567880212 countsByYear W25678802122023 @default.
• W2567880212 crossrefType "journal-article" @default.
• W2567880212 hasAuthorship W2567880212A5035350837 @default.
• W2567880212 hasAuthorship W2567880212A5035895188 @default.
• W2567880212 hasAuthorship W2567880212A5054913838 @default.
• W2567880212 hasAuthorship W2567880212A5068472134 @default.
• W2567880212 hasAuthorship W2567880212A5073006852 @default.
• W2567880212 hasAuthorship W2567880212A5075420379 @default.
• W2567880212 hasAuthorship W2567880212A5076078511 @default.
• W2567880212 hasBestOaLocation W25678802121 @default.
• W2567880212 hasConcept C136449434 @default.
• W2567880212 hasConcept C139964883 @default.
• W2567880212 hasConcept C185592680 @default.
• W2567880212 hasConcept C203014093 @default.
• W2567880212 hasConcept C2522874641 @default.
• W2567880212 hasConcept C2776914184 @default.
• W2567880212 hasConcept C2777209026 @default.
• W2567880212 hasConcept C2777869810 @default.
• W2567880212 hasConcept C2779465607 @default.
• W2567880212 hasConcept C2780593183 @default.
• W2567880212 hasConcept C86803240 @default.
• W2567880212 hasConcept C8891405 @default.
• W2567880212 hasConcept C98274493 @default.
• W2567880212 hasConceptScore W2567880212C136449434 @default.
• W2567880212 hasConceptScore W2567880212C139964883 @default.
• W2567880212 hasConceptScore W2567880212C185592680 @default.
• W2567880212 hasConceptScore W2567880212C203014093 @default.
• W2567880212 hasConceptScore W2567880212C2522874641 @default.
• W2567880212 hasConceptScore W2567880212C2776914184 @default.
• W2567880212 hasConceptScore W2567880212C2777209026 @default.
• W2567880212 hasConceptScore W2567880212C2777869810 @default.
• W2567880212 hasConceptScore W2567880212C2779465607 @default.
• W2567880212 hasConceptScore W2567880212C2780593183 @default.
• W2567880212 hasConceptScore W2567880212C86803240 @default.
• W2567880212 hasConceptScore W2567880212C8891405 @default.

• next